UroLift is a minimally invasive treatment for Benign Prostatic Hyperplasia, a condition that causes an enlarged prostate in ...
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death ...
Scientists based in Australia and China have identified a pair of pesky enzymes responsible for prolonging prostate cancer – ...
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback